Good news!!!Might bring more product to the pipeline or at least more possibility for additional development, GO MIP GO!!!
------------------------------------------------------
Montreal, Quebec, June 6, 2007 – Mistral Pharma Inc. (TSX Venture: MIP) announced today that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a new oral drug delivery platform to be used in some of its pipeline development projects. This oral drug delivery platform was developed by Mistral’s Vice President of R&D, Dr. Alain Desjardins and senior formulator Najiba Dernaoui. The patent application was filed by the Montreal office of Bereskin & Parr, a leading patent agent firm.
“The filing of this patent application shows that Mistral can count on an additional oral delivery platform, which increases the versatility of our technology portfolio” said Mr. Bertrand F. Bolduc, Mistral’s President & CEO. “In addition to Procise™, Savit™ and Chronop™, Mistral can use at least two other platforms in order to develop optimal oral drug delivery formulations” he added.